DE69625678T2 - Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2 - Google Patents

Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2

Info

Publication number
DE69625678T2
DE69625678T2 DE69625678T DE69625678T DE69625678T2 DE 69625678 T2 DE69625678 T2 DE 69625678T2 DE 69625678 T DE69625678 T DE 69625678T DE 69625678 T DE69625678 T DE 69625678T DE 69625678 T2 DE69625678 T2 DE 69625678T2
Authority
DE
Germany
Prior art keywords
breast cancer
relates
brca2
human
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69625678T
Other languages
English (en)
Other versions
DE69625678T3 (de
DE69625678D1 (de
Inventor
Sean V Tavtigian
Alexander Kamb
Jacques Simard
Fergus Couch
Johanna M Rommens
Barbara L Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDO RECHERCHE INC., QUEBEC, CA
HSC Research and Development LP
University of Utah Research Foundation UURF
University of Pennsylvania Penn
Original Assignee
Endorecherche Inc
HSC Research and Development LP
Myriad Genetics Inc
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27541925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69625678(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/639,501 external-priority patent/US5837492A/en
Application filed by Endorecherche Inc, HSC Research and Development LP, Myriad Genetics Inc, University of Pennsylvania Penn filed Critical Endorecherche Inc
Publication of DE69625678D1 publication Critical patent/DE69625678D1/de
Application granted granted Critical
Publication of DE69625678T2 publication Critical patent/DE69625678T2/de
Publication of DE69625678T3 publication Critical patent/DE69625678T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69625678T 1995-12-18 1996-12-17 Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2 Expired - Lifetime DE69625678T3 (de)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US576559 1984-02-03
US57377995A 1995-12-18 1995-12-18
US573779 1995-12-18
US57535995A 1995-12-20 1995-12-20
US575359 1995-12-20
US57655995A 1995-12-21 1995-12-21
US58539196A 1996-01-11 1996-01-11
US585391 1996-01-11
US639501 1996-04-29
US08/639,501 US5837492A (en) 1995-12-18 1996-04-29 Chromosome 13-linked breast cancer susceptibility gene

Publications (3)

Publication Number Publication Date
DE69625678D1 DE69625678D1 (de) 2003-02-13
DE69625678T2 true DE69625678T2 (de) 2003-11-06
DE69625678T3 DE69625678T3 (de) 2006-11-09

Family

ID=27541925

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625678T Expired - Lifetime DE69625678T3 (de) 1995-12-18 1996-12-17 Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2

Country Status (11)

Country Link
US (2) US6124104A (de)
EP (1) EP0785216B2 (de)
JP (1) JP3455228B2 (de)
AT (1) ATE230759T1 (de)
AU (1) AU1461597A (de)
CA (1) CA2239733C (de)
DE (1) DE69625678T3 (de)
IL (1) IL124620A0 (de)
NO (1) NO982785L (de)
NZ (1) NZ326525A (de)
WO (1) WO1997022689A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
CA2273051A1 (en) * 1996-12-03 1998-06-11 Prasanna Athma Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
GB9708221D0 (en) * 1997-04-23 1997-06-11 Cancer Res Campaign Tech Substances and uses thereof
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
EP2275575A3 (de) * 1997-08-15 2012-07-11 Gene Logic Inc. Menschliche BRCA2-Gen-kodierende Sequenzhaplotypen
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6051379A (en) * 1997-09-23 2000-04-18 Oncormed, Inc. Cancer susceptibility mutations of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US7148016B1 (en) * 1999-01-14 2006-12-12 Ca*Tx Inc. Immunoassays to detect diseases or disease susceptibility traits
AUPQ421699A0 (en) * 1999-11-24 1999-12-16 University Of Western Australia, The Tumour suppressor factor
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
US20030093819A1 (en) 2000-11-03 2003-05-15 D'andrea Alan D. Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US20030188326A1 (en) * 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US6816789B2 (en) * 2001-04-19 2004-11-09 Varian, Inc. Method and system for analyzing chromatograms
AU2002323841B2 (en) * 2001-06-05 2008-05-22 Auckland Uniservices Limited Methods and compositions for assessment of pulmonary function and disorders
AU2002359398A1 (en) * 2001-11-16 2003-06-10 Exelixis, Inc. Nucleic acids and polypeptides of invertebrate brca2 and methods of use
CA2468197A1 (en) * 2001-11-29 2003-06-05 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
CA2608142A1 (en) * 2005-05-10 2006-11-16 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
CA2608161A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods for the assesssment of risk of developing lung cancer using analysis of genetic polymorphisms
AU2006248200A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
US7933722B2 (en) * 2005-05-20 2011-04-26 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
PL2134876T3 (pl) * 2006-06-22 2014-10-31 Pomorski Univ Medyczny Określanie predyspozycji do raka piersi poprzez identyfikację kombinacji genotypu specyficznych wariantów genów CYP1B1, BRCA2 oraz CHEK2
WO2008021288A2 (en) * 2006-08-11 2008-02-21 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
US7993835B1 (en) * 2007-05-11 2011-08-09 Myriad Genetics, Inc. BRCA2 mutations and use thereof
EP3075864A1 (de) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signatursets nach tumortyp
CN107254538A (zh) * 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
US20130029926A1 (en) * 2009-11-05 2013-01-31 Myriad Genetics, Inc. Compositions and methods for determing cancer susceptibility
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
US20130018700A1 (en) * 2011-07-14 2013-01-17 International Business Machines Corporation Optimizing product portfolios under customer choice
US20140222512A1 (en) * 2013-02-01 2014-08-07 Goodsnitch, Inc. Receiving, tracking and analyzing business intelligence data
US20140343982A1 (en) * 2013-05-14 2014-11-20 Landmark Graphics Corporation Methods and systems related to workflow mentoring
CN106852176A (zh) * 2014-03-25 2017-06-13 凡弗3基因组有限公司 用于功能证实癌症突变的rna分析的系统和方法
US10133996B2 (en) * 2014-04-22 2018-11-20 International Business Machines Corporation Object lifecycle analysis tool
CN104962613B (zh) * 2015-06-02 2019-12-03 南京医科大学 一种用于乳腺癌辅助诊断的突变基因及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5773278A (en) † 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU1214995A (en) * 1993-11-30 1995-06-19 California Pacific Medical Center Research Institute Cdna probe for breast cancer diagnosis and treatment
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
ATE259378T1 (de) * 1995-11-23 2004-02-15 Cancer Res Campaign Tech Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs- suszeptilitaetsgens brca2 und dessen anwendungen
GB2307477B (en) * 1995-11-23 1997-10-22 Cancer Res Campaign Tech Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
US5879890A (en) † 1997-01-31 1999-03-09 The Johns Hopkins University APC mutation associated with familial colorectal cancer in Ashkenazi jews
CA2289109A1 (en) † 1997-04-30 1998-11-05 Genzyme Limited Carbohydrate-deficient glycoprotein syndrome type i
WO1998055650A1 (en) † 1997-06-04 1998-12-10 Rijksuniversiteit Te Leiden A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
US6376176B1 (en) † 1999-09-13 2002-04-23 Cedars-Sinai Medical Center Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease
BR0109192A (pt) † 2000-03-16 2003-05-27 Sucampo Ag Tratamento de hipertensão ocular e glaucoma.
EP1280814A4 (de) † 2000-04-13 2003-05-14 Genaissance Pharmaceuticals Assoziation der haplotypen des beta2 adrenergenen rezeptors mit der medikamentenwirksamkeit
EP1430081A2 (de) † 2001-06-13 2004-06-23 Centre National De La Recherche Scientifique (Cnrs) Molekuläre komplexe brca1/acc alpha, diagnostische und therapeutische verwendungen

Also Published As

Publication number Publication date
NO982785D0 (no) 1998-06-17
ATE230759T1 (de) 2003-01-15
CA2239733A1 (en) 1997-06-26
IL124620A0 (en) 1998-12-06
EP0785216B2 (de) 2006-06-07
EP0785216B1 (de) 2003-01-08
DE69625678T3 (de) 2006-11-09
CA2239733C (en) 2001-04-03
NO982785L (no) 1998-08-17
WO1997022689A1 (en) 1997-06-26
NZ326525A (en) 1999-11-29
US6033857A (en) 2000-03-07
AU1461597A (en) 1997-07-14
DE69625678D1 (de) 2003-02-13
EP0785216A1 (de) 1997-07-23
JP3455228B2 (ja) 2003-10-14
US6124104A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
DE69625678D1 (de) Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
EP1260520A3 (de) Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
MX9701075A (es) Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
CA2196795A1 (en) Method for diagnosing a predisposition for breast and ovarian cancer
MX9701074A (es) Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
WO2001085911A3 (en) Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION, SALT L

Owner name: ENDO RECHERCHE INC., QUEBEC, CA

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, PH

Owner name: HSC RESEARCH AND DEVELOPMENT LTD. PARTNERSHIP, TOR